AIHC Capital Management Ltd
CIK 2103725 · View on SEC EDGAR ↗
- Portfolio value
- $104.2M
- Positions
- 4
- As of
- June 30, 2026
Portfolio value QoQ: -12.9% 13F does not disclose cash
- Top 10 holdings weight
- 100.00%
- Top 25 holdings weight
- 100.00%
- Positions above 1%
- 3
- Effective number of positions
- 2.2
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 14.31% Est. buys $16,024,729 · sells $100,457,965
- New positions
- 0
- Increased
- 2
- Decreased
- 1
- Closed
- 1
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
Performance vs S&P 500
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 100.0% · Options excluded: 0.0%
Sector breakdown
Full portfolio 4 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines, Inc. - Common Stock | $56,770,748 | 54.46% | 303,133 | $-23,846,974 | Down ×2 | ||
| ORIC Oric Pharmaceuticals, Inc. - Common Stock | $41,462,222 | 39.77% | 3,828,460 | $10,299,711 | Up ×1 | ||
| NBP NovaBridge Biosciences - American Depositary Shares | $5,612,164 | 5.38% | 2,878,033 | $45,349 | Up ×2 | ||
| KRRO Korro Bio, Inc. - Common Stock | $398,893 | 0.38% | 30,265 | $56,293 | |||
| No matches | |||||||
Top movers (QoQ)
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.